IDWeek 2026: ISL/LEN on track to become the first once-weekly oral HIV therapy
At IDWeek 2026, Samir K Gupta presented a pooled analysis of the Phase III ISLEND-1 and ISLEND-2 trials evaluating once-weekly ISL/LEN in adults with virologically suppressed HIV.
